131 related articles for article (PubMed ID: 35583142)
1. Author response to: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
Rahman SA; Underwood TJ
Br J Surg; 2022 Jul; 109(8):e92. PubMed ID: 35583142
[No Abstract] [Full Text] [Related]
2. Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
Liu K; Zhang WH; Hu JK
Br J Surg; 2022 Jul; 109(8):e91. PubMed ID: 35583148
[No Abstract] [Full Text] [Related]
3. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
Rahman S; Thomas B; Maynard N; Park MH; Wahedally M; Trudgill N; Crosby T; Cromwell DA; Underwood TJ
Br J Surg; 2022 Feb; 109(2):227-236. PubMed ID: 34910129
[TBL] [Abstract][Full Text] [Related]
4. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Briasoulis E; Fatouros M; Roukos DH
Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
[No Abstract] [Full Text] [Related]
5. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Advanced Adenocarcinoma at the Esophagogastric Junction That Exhibited pCR by Preoperative SOX Therapy].
Mihara D; Kuwada K; Hamazaki T; Namba K; Takahashi T; Takehara K; Kuise T; Kuroda M; Yamano T; Takagi S; Ikeda E; Kemmotsu M; Ikeda T
Gan To Kagaku Ryoho; 2022 Jun; 49(6):693-696. PubMed ID: 35799398
[TBL] [Abstract][Full Text] [Related]
7. Gastro-oesophageal junction: to FLOT or to CROSS?
van den Ende T; Hulshof MCCM; van Berge Henegouwen MI; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2020 Feb; 59(2):233-236. PubMed ID: 31813320
[No Abstract] [Full Text] [Related]
8. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
Haag GM; Byl A; Jäger D; Berger AK
Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
[TBL] [Abstract][Full Text] [Related]
9. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
10. Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers.
Ku GY
Surg Oncol Clin N Am; 2017 Apr; 26(2):241-256. PubMed ID: 28279467
[TBL] [Abstract][Full Text] [Related]
11. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma.
Ilson DH; Al-Batran SE
Lancet Oncol; 2023 Jun; 24(6):593-595. PubMed ID: 37269840
[No Abstract] [Full Text] [Related]
13. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
[TBL] [Abstract][Full Text] [Related]
14. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
Schmidt T; Alldinger I; Blank S; Klose J; Springfeld C; Dreikhausen L; Weichert W; Grenacher L; Bruckner T; Lordick F; Ulrich A; Büchler MW; Ott K
Eur J Surg Oncol; 2015 Oct; 41(10):1340-7. PubMed ID: 26213358
[TBL] [Abstract][Full Text] [Related]
15. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
17. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
18. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Chua YJ; Cunningham D
Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
[No Abstract] [Full Text] [Related]
19. Cancer of the gastroesophageal junction: combined modality therapy.
Ilson DH
Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
[TBL] [Abstract][Full Text] [Related]
20. [Role of the pathologist in the processing of adenocarcinoma of the stomach, oesophagogastric junction and lower third of the oesophagus].
Svrcek M; Fléjou JF
Ann Pathol; 2011 Dec; 31(6):419-26. PubMed ID: 22172114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
